World Wide Tax News - Issue 50

World Wide Tax News - Issue 50

BDO World Wide Tax News summarises recent tax developments of international interest across the world. 

Read the World Wide Tax News

Related Resources

mic_none
Podcast

Tax at the Speed of Tech Podcast: More Innovation Coming in Season 2

September 27, 2023
Podcast

Tax at the Speed of Tech Podcast: More Innovation Coming in Season 2

September 27, 2023

In this teaser episode, host Chris D’Ambola speaks with Haley Dobre, a BDO partner and Tax Automation & Innovation practice leader, to recap what we learned in season one, what to expect from season two, and the importance of these conversations in today’s dynamic business environment.

Read More

Article

IRS Stops Processing New Employee Retention Credit Claims, Urges Employers to Seek Trusted Tax Professionals for Help

September 27, 2023
Article

IRS Stops Processing New Employee Retention Credit Claims, Urges Employers to Seek Trusted Tax Professionals for Help

September 27, 2023

On September 14, 2023, the IRS published Information Release (IR) 2023-169 announcing IRS Commissioner Danny Werfel’s order to immediately stop processing new employee retention credit (ERC) claims. The moratorium will be in place at least through December 31, 2023.

Read More

Article

The SALT Implications of Moore v. United States

September 27, 2023
Article

The SALT Implications of Moore v. United States

September 27, 2023

On June 26, the U.S. Supreme Court agreed to review a challenge to the constitutionality of the repatriation tax in Internal Revenue Code Section 965, a one-time mandatory transition tax imposed on U.S. shareholders of some foreign corporations measured by the corporations’ untaxed foreign earnings.

Read More

Article

Pharma Wins Again on Deducting Patent Dispute Costs for Generics

September 25, 2023
Article

Pharma Wins Again on Deducting Patent Dispute Costs for Generics

September 25, 2023

An appellate court has affirmed that the legal fees a maker of a new generic drug pays in defending against patent infringement claims arising from its application to the FDA need not be treated as a cost of obtaining an intangible asset. Read the full article to learn more.

Read More